MGX
Metagenomi, Inc.
1.00$
-1.0%
vs. previous close
Closing price · As of: Oct 6, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | – | 100.0% | |
| 217.1% | 199.7% | 281.7% | 6.5% | – | 15.2% | 609.2% | 264.4% | 15.3% | 33.2% | 69.2% | – | – | |
| -117.1% | -99.7% | -181.7% | 100.0% | 100.0% | 100.0% | -509.2% | -164.4% | 84.7% | 66.8% | 30.8% | – | 74.3% | |
| 217.1% | 199.7% | 281.7% | 141.5% | 228.0% | 240.9% | 609.2% | 264.4% | 276.7% | 549.8% | 1,546.5% | – | 643.6% | |
| 64.1% | 63.2% | 78.4% | 42.7% | 66.4% | 73.6% | 164.9% | 82.1% | 71.8% | 173.3% | 523.6% | – | 188.3% | |
| 64.1% | 63.2% | 78.4% | 184.3% | 294.4% | 314.5% | 164.9% | 82.1% | 348.5% | 689.8% | 2,001.0% | – | 815.9% | |
| -181.1% | -162.9% | -260.2% | -84.3% | -194.4% | -214.5% | -674.1% | -246.5% | -263.8% | -623.0% | -1,970.1% | – | -741.6% | |
| 0.0% | 0.0% | – | – | – | – | – | – | – | – | – | – | – | |
| -150.6% | -133.6% | -225.4% | -64.7% | -181.3% | -255.9% | -604.3% | -233.3% | -238.2% | -575.1% | -1,846.9% | – | -690.6% | |
| 9.8% | 22.0% | -35.3% | -11.0% | -18.3% | -12.6% | 2.4% | 0.5% | -2.7% | 0.9% | -0.8% | – | – | |
| -160.3% | -155.6% | -225.4% | -53.7% | -163.0% | -243.4% | -606.7% | -233.9% | -235.5% | -576.0% | -1,847.7% | – | -689.2% | |
| -141.2% | -123.9% | -214.0% | -58.1% | -169.5% | -240.7% | -571.4% | -217.7% | -222.9% | -541.9% | -1,744.7% | – | -652.5% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 6, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.